Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

IMPORT-201: A Phase 1 First-in-Human Dose Finding/Randomized Phase 2 Study of IMM60 and Pembrolizumab for Advanced Melanoma and Metastatic NSCLC

NCT05709821 is registered in ClinicalTrials.gov with iOx Therapeutics as lead sponsor.

NCT NCT05709821
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05709821 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
IMPORT-201: A Phase 1 First-in-Human Dose Finding/Randomized Phase 2 Study of IMM60 and Pembrolizumab for Advanced Melanoma and Metastatic NSCLC
Lead sponsor
iOx Therapeutics
Phase
Phase 1/2
Overall status
Terminated
Start date
November 15, 2023
Completion date
April 22, 2024
Enrollment
1 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma, non-small cell lung cancer